Compare LII & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LII | EXEL |
|---|---|---|
| Founded | 1895 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 12.7B |
| IPO Year | 1999 | 2000 |
| Metric | LII | EXEL |
|---|---|---|
| Price | $363.31 | $57.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 21 |
| Target Price | ★ $566.58 | $46.50 |
| AVG Volume (30 Days) | 439.3K | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | 1.11 | ★ 57.95 |
| EPS | ★ 3.35 | 1.60 |
| Revenue | ★ $5,195,300,000.00 | $452,477,000.00 |
| Revenue This Year | $6.85 | $13.61 |
| Revenue Next Year | $5.76 | $13.13 |
| P/E Ratio | $107.27 | ★ $36.39 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $350.22 | $33.76 |
| 52 Week High | $587.27 | $59.72 |
| Indicator | LII | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 52.84 |
| Support Level | $350.22 | $54.38 |
| Resistance Level | $396.21 | $57.12 |
| Average True Range (ATR) | 10.70 | 1.62 |
| MACD | 1.88 | -0.04 |
| Stochastic Oscillator | 29.59 | 48.70 |
Lennox manufactures and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounts for 67% of sales and commercial HVAC (building climate solutions) accounts for the remaining 33% of sales. Lennox's commercial exposure is what its peers refer to as residential and light commercial, and lacks the scale and complexity of what is referred to as an applied solution. The company goes to market with multiple brands, but Lennox is its flagship HVAC brand.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.